SCHEDULE: Samda Biolab Discloses 5.1% Stake in Liminatus Pharma

Samda Biolab Co., Ltd. has reported beneficial ownership of 3,426,548 shares, representing 5.1% of Liminatus Pharma, Inc.'s common stock.

Summary

• Samda Biolab Co., Ltd. has filed a Schedule 13G, indicating it beneficially owns 3,426,548 shares of Liminatus Pharma, Inc. common stock.
• This ownership stake represents 5.1% of the total outstanding common stock.
• The filing date for this event is July 2, 2026.
• The calculation of the percentage is based on 67,160,362 shares of common stock outstanding as of July 2, 2026.
• Samda Biolab Co., Ltd. is a South Korean entity.
• The filing certifies that the securities were not acquired to influence or change the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It's a standard disclosure of a significant ownership stake without immediate indicators of positive or negative performance or strategic shifts for Liminatus Pharma.

Positives

• Samda Biolab Co., Ltd. has acquired a significant minority stake (5.1%) in Liminatus Pharma, Inc., potentially indicating confidence in the company's future.
• The clear disclosure of ownership provides transparency to the market regarding a substantial shareholder.

Risks

• While not explicitly stated as a risk, any significant change in ownership or voting power by Samda Biolab could potentially influence Liminatus Pharma's strategic direction.
• The filing does not provide details on the purpose of the investment, leaving potential strategic intentions open to interpretation.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Liminatus Pharma, Inc. It solely reports on the ownership stake of Samda Biolab Co., Ltd.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant stakeholders acquiring more than 5% of a company's stock. This filing indicates Samda Biolab's entry into a substantial ownership position in Liminatus Pharma, a move that could signal strategic interest or a passive investment.

Stakeholder Impact

• Shareholders: The acquisition of a 5.1% stake by Samda Biolab may be viewed positively as it suggests external confidence in the company, but it also introduces a significant shareholder whose future actions could impact share price and corporate strategy.
• Management: The certification by Samda Biolab that the shares were not acquired to influence control suggests a potentially passive investment, which may be reassuring to current management.

Key Dates

Recommendation

This filing is a disclosure of ownership and does not provide operational or financial performance data for Liminatus Pharma. Therefore, a 'hold' recommendation is appropriate as it reflects the need for further information before making a buy or sell decision.

Keywords

Liminatus Pharma, Samda Biolab, Schedule 13G, Beneficial Ownership, Common Stock, Shareholder, South Korea